ICU Medical (NASDAQ:ICUI) Earns "Sell (D-)" Rating from Weiss Ratings

ICU Medical (NASDAQ:ICUI - Get Free Report)'s stock had its "sell (d-)" rating restated by stock analysts at Weiss Ratings in a report issued on Wednesday,Weiss Ratings reports.

Other equities research analysts have also issued reports about the company. Wall Street Zen raised ICU Medical from a "hold" rating to a "buy" rating in a research report on Friday, September 5th. Piper Sandler raised their price target on ICU Medical from $145.00 to $153.00 and gave the company an "overweight" rating in a report on Wednesday, September 10th. Finally, Raymond James Financial lowered their price target on ICU Medical from $187.00 to $180.00 and set a "strong-buy" rating on the stock in a report on Friday, August 8th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $181.00.

ICU Medical Trading Up 1.9%

Shares of ICUI stock opened at $120.31 on Wednesday. The firm has a 50-day moving average price of $124.83 and a 200 day moving average price of $131.40. ICU Medical has a twelve month low of $107.00 and a twelve month high of $196.26. The company has a market capitalization of $2.97 billion, a price-to-earnings ratio of -79.15 and a beta of 0.83. The company has a current ratio of 2.44, a quick ratio of 1.17 and a debt-to-equity ratio of 0.63.

ICU Medical (NASDAQ:ICUI - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The medical instruments supplier reported $2.10 EPS for the quarter, beating analysts' consensus estimates of $1.44 by $0.66. The company had revenue of $543.57 million during the quarter, compared to the consensus estimate of $543.33 million. ICU Medical had a negative net margin of 1.56% and a positive return on equity of 7.24%. The company's quarterly revenue was down 8.0% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.56 EPS. ICU Medical has set its FY 2025 guidance at 6.850-7.15 EPS. Research analysts forecast that ICU Medical will post 4.11 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other ICU Medical news, Director David C. Greenberg acquired 1,200 shares of the firm's stock in a transaction on Wednesday, August 27th. The stock was purchased at an average cost of $126.42 per share, for a total transaction of $151,704.00. Following the transaction, the director owned 7,960 shares of the company's stock, valued at $1,006,303.20. The trade was a 17.75% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Vivek Jain acquired 21,929 shares of the firm's stock in a transaction on Thursday, August 14th. The shares were acquired at an average price of $112.84 per share, with a total value of $2,474,468.36. Following the completion of the transaction, the chief executive officer directly owned 130,149 shares in the company, valued at approximately $14,686,013.16. This trade represents a 20.26% increase in their position. The disclosure for this purchase can be found here. Company insiders own 1.50% of the company's stock.

Institutional Investors Weigh In On ICU Medical

A number of institutional investors have recently bought and sold shares of ICUI. Cullen Frost Bankers Inc. acquired a new stake in ICU Medical during the 2nd quarter worth about $38,000. GAMMA Investing LLC raised its stake in shares of ICU Medical by 27.2% during the 1st quarter. GAMMA Investing LLC now owns 716 shares of the medical instruments supplier's stock worth $99,000 after purchasing an additional 153 shares in the last quarter. Blue Trust Inc. raised its stake in shares of ICU Medical by 23.0% during the 1st quarter. Blue Trust Inc. now owns 801 shares of the medical instruments supplier's stock worth $111,000 after purchasing an additional 150 shares in the last quarter. Smartleaf Asset Management LLC raised its stake in shares of ICU Medical by 11.6% during the 2nd quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier's stock worth $128,000 after purchasing an additional 101 shares in the last quarter. Finally, Headlands Technologies LLC purchased a new stake in shares of ICU Medical during the 2nd quarter worth about $177,000. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.